Formula Grant R43IP001225

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

This SBIR Phase I award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Palena Therapeutics, Inc., a woman-owned small business located in Worcester, MA, to develop a novel class of peptide-based immunomodulators for treating autoimmune and inflammatory disorders, particularly in pediatric patients. The project aims to identify candidate compounds that can re-program the immune system from a pro-inflammatory...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $1,246,617.00 to develop computational models that can accurately predict the breadth and durability of influenza vaccine responses. The key products and services to be delivered under this award include: Capturing and standardizing existing data on influenza vaccine responses and generating new experimental...

This SBIR Phase I award from the National Science Foundation (NSF) under the CFDA 47.084 Technology, Innovation, and Partnerships (TIP) program provides $305,000 to Absco Therapeutics, Inc. (Abscotx) to develop an image-guided intratumoral delivery system for administering biologic immunotherapies to treat solid tumors. The project aims to improve the localization, stability, and controlled release of these biologics within the tumor microenvironment, addressing challenges with current...

This $1,008,000 Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports Vcreate, Inc., a minority-owned small disadvantaged business, in developing a high-throughput platform for screening and identifying T-cell receptors (TCRs) that can target cancer antigens. The objective is to discover and validate clinically relevant TCRs that could serve as the basis for new immunotherapies against solid...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) in the amount of $414,649 aims to develop a new computational environment called HLA-ARENA 2.0 that will integrate existing resources with new bioinformatics methods for structural modeling and analysis of key cellular immunity receptors. The goal is to leverage multi-omics data and large-scale structural analysis to overcome limitations in existing pipelines for...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC to develop a combinatorial high-throughput platform for generating improved molecular recognition components for use in therapeutic and diagnostic antibodies. The core aim is to utilize breakthroughs in DNA sequencing, synthetic biology, and computational biology to efficiently identify and optimize antibody...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,921 to Ubiquitx Inc., a New York-based biotechnology company, to develop a therapeutic platform for upregulating antigen presentation to enhance immune surveillance of diseased cells. The award supports the development and characterization of Ubiquitinase Chimeric Ligands for Induced Proximity (UbiClips)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $270,176 in funding to Oncosting, LLC to develop an improved tuberculosis (TB) vaccine candidate designated OS-151. The award supports two phases of work: In Phase I, the project will conduct mouse immunogenicity and efficacy studies to support using data generated with the OS-101 strain in regulatory filings for the...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $534,000.00 in funding to The Children's Hospital of Philadelphia Research Institute to conduct research on CD4+ T cell differentiation. The research aims to investigate how the location of antigen and the density and half-life of peptide:MHCII complexes on antigen-presenting cells can influence the expansion...